Esperion Therapeutics (ESPR)
NASDAQ:ESPR
Want to see ESPR full AI Analyst Report?
ESPR Stock Chart & Stats
$2.04
-$0.02(-0.92%)
At close: 4:00 PM EST
$2.04
-$0.02(-0.92%)
Day’s Range― - ―
52-Week Range$0.95 - $4.18
Previous CloseN/A
Volume1.55M
Average Volume (3M)11.23M
Market Cap
$811.73M
Enterprise Value$755.54M
Total Cash (Recent Filing)$156.16M
Total Debt (Recent Filing)$252.63M
Price to Earnings (P/E)―
Beta1.88
Next Earnings
Aug 04, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding257,693,360
10 Day Avg. Volume9,667,582
30 Day Avg. Volume11,232,602
Financial Highlights & Ratios
PEG Ratio0.56
Price to Book (P/B)-2.55
Price to Sales (P/S)1.91
P/FCF Ratio-58.74
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue1.81
Enterprise Value/Gross Profit2.78
Enterprise Value/Ebitda18.94
Forecast
1Y Price Target
$2.91Price Target Upside42.55% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$387.62M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Margin RecoveryA multi-year revenue inflection with sales quadrupling since 2023 and a ~20% operating margin indicates durable commercial traction for core products. Sustained top-line scale and positive operating margins improve structural earnings power and support reinvestment or debt reduction over the next several quarters.
Portfolio Diversification Via Corstasis AcquisitionAdding Enbumyst and Corstasis' assets diversifies the product mix beyond bempedoic acid, leveraging Esperion's commercial infrastructure to address acute-adjacent outpatient opportunities. This structural diversification reduces single-product exposure and can provide near-term revenue without long R&D lead times.
Take-private Deal Progress And Committed FinancingRegulatory progress toward the ArchiMed/Essence buyout plus announced committed financing provides an enduring change in capital structure prospects. Access to private equity funding and deal certainty reduces near-term refinancing risk and can enable longer-term strategic investments away from public market pressures.
Bears Say
Negative Shareholders' EquityA sustained negative equity balance (~-$308M TTM) signals a weak capital base and makes the company more sensitive to setbacks. Even with improving operations, negative equity constrains financial flexibility, elevates refinancing and covenant risks, and limits capacity to absorb shocks without external capital.
Negative Operating And Free Cash FlowRepeated negative operating and free cash flow (TTM ~-$18.2M) shows the company has not yet proven consistent self-funding. This structural cash deficit necessitates continued external financing, asset monetization, or deal-related funding, constraining long-term investment flexibility and increasing liquidity risk.
Revenue Concentration & Partner DependenceCommercial success remains tied to U.S. prescription uptake and partner execution abroad. Reliance on payer coverage, formulary positioning, and third-party partners for international royalties creates persistent execution and reimbursement risks that can materially affect revenues and the firm’s path to sustained profitability.
Esperion News
ESPR FAQ
What was Esperion Therapeutics’s price range in the past 12 months?
Esperion Therapeutics lowest stock price was $0.95 and its highest was $4.17 in the past 12 months.
What is Esperion Therapeutics’s market cap?
Esperion Therapeutics’s market cap is $811.73M.
When is Esperion Therapeutics’s upcoming earnings report date?
Esperion Therapeutics’s upcoming earnings report date is Aug 04, 2026 which is in 45 days.
How were Esperion Therapeutics’s earnings last quarter?
Esperion Therapeutics released its earnings results on May 07, 2026. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.037 by -$0.063.
Is Esperion Therapeutics overvalued?
According to Wall Street analysts Esperion Therapeutics’s price is currently Undervalued.
Does Esperion Therapeutics pay dividends?
Esperion Therapeutics does not currently pay dividends.
What is Esperion Therapeutics’s EPS estimate?
Esperion Therapeutics’s EPS estimate is >-0.01.
How many shares outstanding does Esperion Therapeutics have?
Esperion Therapeutics has 257,693,360 shares outstanding.
What happened to Esperion Therapeutics’s price movement after its last earnings report?
Esperion Therapeutics reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.037. Following the earnings report the stock price went down -0.317%.
Which hedge fund is a major shareholder of Esperion Therapeutics?
Currently, no hedge funds are holding shares in ESPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Esperion Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.91 (42.55% Upside)
$2.91 (42.55% Upside)
Blogger Sentiment
Neutral
ESPR Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $342.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.4%
Last 30 Days ▼ 13.2%
Last 30 Days ▼ 13.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
186.36%
12-Months-Change
Fundamentals
Return on Equity
1.99%
Trailing 12-Months
Asset Growth
42.74%
Trailing 12-Months
Company Description
Esperion Therapeutics
Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In addition, Esperion maintains a licensing and collaborative partnership with Daiichi Sankyo Europe GmbH, alongside an agreement with Serometrix to acquire rights to an oral, small molecule PCSK9 inhibitor program. Established in 2008, the company's corporate offices are situated in Ann Arbor, Michigan.
ESPR Company Deck
ESPR Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong commercial and financial highlights: record revenue growth (Q4 +144%), meaningful U.S. product momentum (U.S. sales +38%; Rx equivalents +34%; prescribers +~25%), expanding international adoption (Daiichi +51% royalties; >700,000 patients treated), a stronger balance sheet ($167.9M cash and $55M debt paid), and a strategic acquisition (Corstasis/Enbumyst) that broadens market opportunity. Lowlights were largely transitional or one-time in nature: a large nonrecurring collaboration payment in 2025 that reduces revenue comparability in 2026, rising SG&A/legal costs tied to litigation, modestly higher R&D and operating expense guidance to fund integration and launches, and near-term uncertainty from guideline timing and competitive entrants. Overall, the positives — robust growth, global rollout, pipeline advancement, and a transformative acquisition — outweigh the manageable near-term challenges and one-time items.View all ESPR earnings summariesESPR Stock 12 Month Forecast
Average Price Target
$2.91
▲(42.55% Upside)
Technical Analysis
Ownership Overview
1.77% Insiders
13.59% Mutual Funds
26.39% Other Institutional Investors
46.44% Public Companies and
Individual Investors